Adial Pharmaceuticals, Inc. (AZR) stock
AZRNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ADIL
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q/A on Oct 21, 2026Score 5/30
Share price
Not available yet
Price, market cap and P/E appear here once daily prices are connected.
Adial Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Adial Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $2.01M, down 37.9% year over year. For fiscal 2025 it was $2.62M, down 18.9% from the year before. The highest annual figure on record is $8.40M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.62M | -18.9% |
| FY2024 | Dec 31, 2024 | $3.23M | +154.9% |
| FY2023 | Dec 31, 2023 | $1.27M | -35.0% |
| FY2022 | Dec 31, 2022 | $1.95M | -76.8% |
| FY2021 | Dec 31, 2021 | $8.40M | +43.4% |
| FY2020 | Dec 31, 2020 | $5.85M | +47.6% |
| FY2019 | Dec 31, 2019 | $3.97M | +976.3% |
| FY2018 | Dec 31, 2018 | $368.46K | +102.3% |
| FY2017 | Dec 31, 2017 | $182.11K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $440.00K | -39.9% |
| Q1 FY2026 | Mar 31, 2026 | $432.53K | -42.1% |
| Q4 FY2025 | Dec 31, 2025 | $619.40K | -15.2% |
| Q3 FY2025 | Sep 30, 2025 | $521.07K | -49.5% |
| Q2 FY2025 | Jun 30, 2025 | $732.00K | -27.7% |
| Q1 FY2025 | Mar 31, 2025 | $746.89K | +64.4% |
| Q4 FY2024 | Dec 31, 2024 | $730.79K | +176.4% |
| Q3 FY2024 | Sep 30, 2024 | $1.03M | +398.1% |
| Q2 FY2024 | Jun 30, 2024 | $1.01M | +135.5% |
| Q1 FY2024 | Mar 31, 2024 | $454.28K | +24.3% |
| Q4 FY2023 | Dec 31, 2023 | $264.44K | -50.3% |
| Q3 FY2023 | Sep 30, 2023 | $207.13K | -70.2% |
| Q2 FY2023 | Jun 30, 2023 | $429.90K | -36.8% |
| Q1 FY2023 | Mar 31, 2023 | $365.62K | -38.7% |
| Q4 FY2022 | Dec 31, 2022 | $531.84K | -77.2% |
| Q3 FY2022 | Sep 30, 2022 | $696.07K | -58.9% |
| Q2 FY2022 | Jun 30, 2022 | $679.97K | -70.7% |
| Q1 FY2022 | Mar 31, 2022 | $596.34K | -70.9% |
| Q4 FY2021 | Dec 31, 2021 | $2.33M | +13.1% |
| Q3 FY2021 | Sep 30, 2021 | $1.69M | -8.4% |
| Q2 FY2021 | Jun 30, 2021 | $2.32M | +161.2% |
| Q1 FY2021 | Mar 31, 2021 | $2.05M | +93.6% |
| Q4 FY2020 | Dec 31, 2020 | $2.06M | +71.4% |
| Q3 FY2020 | Sep 30, 2020 | $1.85M | +113.7% |
| Q2 FY2020 | Jun 30, 2020 | $888.01K | -26.6% |
| Q1 FY2020 | Mar 31, 2020 | $1.06M | +54.3% |
| Q4 FY2019 | Dec 31, 2019 | $1.20M | +2428.1% |
| Q3 FY2019 | Sep 30, 2019 | $864.28K | +358.7% |
| Q2 FY2019 | Jun 30, 2019 | $1.21M | +1474.1% |
| Q1 FY2019 | Mar 31, 2019 | $686.91K | +1137.5% |
| Q4 FY2018 | Dec 31, 2018 | $47.62K | -8.4% |
| Q3 FY2018 | Sep 30, 2018 | $188.44K | +577.9% |
| Q2 FY2018 | Jun 30, 2018 | $76.90K | +32.9% |
| Q1 FY2018 | Mar 31, 2018 | $55.51K | – |
| Q4 FY2017 | Dec 31, 2017 | $51.97K | – |
| Q3 FY2017 | Sep 30, 2017 | $27.80K | – |
| Q2 FY2017 | Jun 30, 2017 | $57.86K | – |